MA-BATTERY-VENTURES
17.4.2024 12:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, announced the acquisition of Labguru (BioData Inc.), the life-science laboratory-data platform, from Holtzbrinck Digital. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417562351/en/
Labguru provides a comprehensive laboratory data-management hub for planning and tracking; documenting experiments; streamlining lab logistics; and sharing results across teams and organizations. Labguru’s easy-to-use, cloud-based, research-to-production life-science platform combines an Electronic Lab Notebook (ELN), a Laboratory Information Management System (LIMS) and a set of informatics tools to enable and enhance research and production. Labguru is trusted by hundreds of thousands of scientists across the biotechnology, pharmaceutical and advanced-industry segments, as well as researchers at global academic and research institutions.
Labguru will join Battery’s Titian Software to create a global organization that offers an end-to-end solution across life sciences and laboratory applications from research to production, spanning the entire workflow from ELN to inventory and sample management, research, testing and QC workflows.
“Together Titian and Labguru will use the investment by Battery to further support organic growth as well as shape the direction of the group’s future acquisitions, in fulfilling the group vision to become the one-stop shop of the global life-science software market,” said Battery General Partner Jesse Feldman.
“We are excited to bring together Titian and Labguru and to work with the companies’ leaders to provide an integrated laboratory and sample-management offering to researchers,” Feldman said. “The two companies already serve researchers across multiple disciplines at the forefront of science, and we look forward to expanding how we serve our customers.”
Labguru’s executive team, including CEO Ariel Yarnitsky and founder and CTO Jonathan Gross, will remain in their current roles, working alongside the Titian executive team following the transaction.
“We’re excited to join forces with Battery, a long-standing investor with domain expertise across life-science informatics and laboratory automation and leverage their vast experience during Labguru’s next growth phase,” said Yarnitsky. “Specifically, Labguru’s mission to build a leading solution catering to the broad needs of scientists in one coherent and easy-to-use platform becomes even more exciting by joining hands with Titian and with the strong support of Battery. Between the additional capital from Battery and the product and cultural fit with Titian, we could not think of a more suitable partner to propel Labguru forward.”
Founder Gross added: “Partnering with Battery and Titian will accelerate our ability to leverage technology, experience and insights to effectively widen the scope of our platform, benefiting science and scientists. This is an important and dramatic step in Labguru’s journey. Further, with Battery Ventures’ long-standing experience investing in data and AI companies, we have found a valuable partner to help shape our vision as we continue building on Labguru’s suite of artificial intelligence tools.”
Titian Software Founder and Chief Product Officer Edmund Wilson added, “We are delighted to partner with Labguru. Our companies share a common commitment to providing state-of-the-art solutions to the life sciences community, delivered by staff who offer tremendous domain expertise.”
Holtzbrinck Digital played a crucial role in Labguru's development and success. Their vision and support have been instrumental in the company's fast growth and positioning as a tier-1 lab-management software company. "We are extremely happy with Labguru's development over the last years and are proud of the strides we've made together. Finding a partner like Battery, who shares our commitment to innovation and excellence, marks a thrilling next chapter for Labguru," said Marc-Orell Dedorath, head of group M&A at Holtzbrinck.
“We are thrilled to unite two major forces in a market that's only beginning to realize its vast potential,” added Justin Rosner, a principal at Battery. “We look forward to working with the Labguru and Titian teams as we embark on this journey together."
About Labguru (BioData Inc.)
Labguru (BioData Inc.) was founded in 2007 and is the developer of a secure, cloud-based laboratory data management platform for life science research and industry. Labguru is an all-in-one platform that streamlines laboratory operations by recording and managing data and inventory, offering molecular biology and chemistry tools, enabling lab automation, and providing data-driven, AI-assisted insights for increased efficiency. As a trusted tool for more than 120,000 scientists worldwide, we empower the digitalization efforts of customers ranging from start-ups to global life science organizations. To learn more about Labguru, visit www.labguru.com.
About Titian Software
Titian Software was founded in 1999 and is a leading provider of sample management software solutions, catering to the unique needs of research laboratories, biobanks, and pharmaceutical companies worldwide. Titian's Mosaic Sample Management Software encompasses a comprehensive suite of tools for sample tracking, inventory management, and workflow automation. Mosaic empowers laboratories to efficiently manage vast repositories of samples, including compounds, biological materials, and clinical specimens while ensuring data integrity and traceability throughout the sample lifecycle. www.titian.co.uk.
About Battery Ventures
Battery partners with exceptional founders and management teams, developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT, and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com, and find a complete list of Battery's portfolio companies here.
About Holtzbrinck Digital
Holtzbrinck Digital manages the investments of the Holtzbrinck Publishing Group in digital startups in the science and education sector, as well as other areas of strategic importance. Holtzbrinck Digital supports them in their development with expertise, resources, and a long-term commitment, enabling the companies to achieve the best possible development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417562351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom